Core Viewpoint - Elutia Inc. has confirmed that the ongoing global tariff environment has not materially impacted its commercial or operational performance, thanks to its U.S.-based operations and vertically integrated manufacturing strategy [1][3]. Company Operations - Elutia sources, manufactures, and distributes 100% of its products within the United States, primarily from its Roswell, Georgia production facility [2]. - The company's product offerings include EluPro™, CanGaroo, SimpliDerm, and a full Cardiovascular portfolio, with all sales occurring domestically [2]. Management Statements - Dr. Randy Mills, CEO of Elutia, emphasized the company's pride in being U.S.-based and highlighted that their operations remain insulated from tariff uncertainties, allowing for reliable production and delivery of medical products [3]. - The Roswell facility is FDA-registered and has not faced delays, cost increases, or supplier issues related to tariffs, positioning the company well to serve the U.S. market without affecting pricing or margins [3]. Company Mission - Elutia develops and commercializes drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients, with a mission to humanize medicine [4].
Elutia Confirms No Material Impact from Global Tariffs